Evidence map›Paper›PMID 41021031›Full record

ArticleWorld journal of urology2025

Association of area of deprivation index with magnetic resonance imaging (MRI) utilization for prostate cancer detection: results from a contemporary North American population.

Alessandro Bertini, Alex Stephens, Alessio Finocchiaro, Silvia Viganò, Arjun Dinesh, Elnaz Guivatchian, Nicholas Cusmano, Giovanni Lughezzani, Nicolò Buffi, Gabriele Sorce and 7 more

Abstract read
PubMed Publisher
In one paragraph

Article in World journal of urology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Alessandro BertiniVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.ORCID http://orcid.org/0009-0004-4987-7898
Alex StephensPublic Health Sciences, Henry Ford Health System, Detroit, MI, USA.
Alessio FinocchiaroVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Silvia ViganòVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Arjun DineshVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Elnaz GuivatchianSchool of Medicine, Wayne State University, Detroit, MI, USA.
Nicholas CusmanoVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Giovanni LughezzaniDepartment of Urology, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy.
Nicolò BuffiDepartment of Urology, IRCCS Humanitas Research Hospital, Humanitas University, Milan, Italy.
Gabriele SorceDepartment of Clinical and Experimental Medicine, Department of Oncology, Urologic section, AOU G. Martino, University of Messina, Messina, Italy.
Vincenzo FicarraDepartment of Clinical and Experimental Medicine, Department of Oncology, Urologic section, AOU G. Martino, University of Messina, Messina, Italy.
Alberto BrigantiDivision of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Andrea SaloniaDivision of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Francesco MontorsiDivision of Oncology, Unit of Urology, IRCCS Ospedale San Raffaele, Vita-Salute San Raffaele University, Milan, Italy.
Akshay SoodDepartment of Urology, The James Cancer Hospital and Solove Research Institute, The Ohio State University Wexner Medical Center, Columbus, OH, USA.
Craig RogersVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA.
Firas AbdollahVUI Center for Outcomes Research, Analysis, and Evaluation, Henry Ford Health System, 2799 W Grand Blvd, Detroit, MI, 48202, USA. Fabdoll1@hfhs.org.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeSince the use of Magnetic Resonance Imaging (MRI) in the initial diagnostic evaluation for prostate cancer (PCa) has considerable costs, there is concern that socioeconomic barriers may result in MRI underutilization. We examined the relationship between socioeconomic factors, measured by the Area Deprivation Index (ADI), and MRI utilization in PCa diagnostic setting using a contemporary North American population.

methodsWe included all the patients aged > 40 years with a confirmed PSA > 3 ng/mL at Henry Ford Health (HFH) between 2018 and 2022. An ADI score was assigned to each patient based on their residential census block group, ranked as a percentile of deprivation relative to the national level. The higher the ADI, the more the area has a socio-economic disadvantage. MRI and biopsy status were defined as undergoing these procedures within 6 and 9 months, respectively, from their first PSA > 3 ng/mL in the time period. Univariable (UVA) and multivariable (MVA) Logistic regression models tested the impact of ADI on prostate MRI or biopsy utilization.

resultsWe included 18,827 patients who had a PSA > 3 ng/mL, 3759 (20%) of whom were Non-Hispanic Black. Overall, 679 (3.6%) and 1672 (8.8%) of these individuals underwent prostatic MRI and prostate biopsy, respectively. Median (IQR) age and ADI percentile were 68 (62-74) years and 58 (38-79), respectively. Patients who received MRI were more likely to be younger (66 vs. 68, p = 0.006), Non-Hispanic Black [28.0% (95%CI: 24.7%-31.5%) vs. 19.7% (95% CI 19.1%-20.3%), p < 0.0001] and to undergo PSA test in more recent median years (2021 vs. 2019, p < 0.0001), compared to those who did not undergo MRI. When stratifying the population by ADI quintiles, men in the fifth (most deprived) quintile were less likely to receive MRI (3.1% vs. 5.9%, p < 0.001), compared to those in the first (most affluent) quintile. At logistic MVA, patients living in more deprived neighborhoods (higher ADI percentile) were less likely to receive MRI before PCa diagnosis (OR: 0.90, p < 0.001). Specifically, for an increase in ADI percentile of 10 units, the relative odds of receiving MRI decreased by 10%.

conclusionsAlthough the overall utilization of prostate MRI remains low in this real-world study, men living in more socioeconomically deprived areas were significantly less likely to undergo MRI before PCa diagnosis. Our findings underscore the need for targeted interventions to ensure a more equitable access to advanced diagnostic tools.

Indexed as

Magnetic Resonance ImagingProstatic NeoplasmsAdultAgedHumansMaleMiddle AgedRetrospective StudiesSocioeconomic FactorsDiagnosisHealth disparitiesMagnetic resonance imagingProstate cancer

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.